[go: up one dir, main page]

HK1153648A1 - Methods for increasing or decreasing bone density and identifying molecules - Google Patents

Methods for increasing or decreasing bone density and identifying molecules Download PDF

Info

Publication number
HK1153648A1
HK1153648A1 HK11107767.3A HK11107767A HK1153648A1 HK 1153648 A1 HK1153648 A1 HK 1153648A1 HK 11107767 A HK11107767 A HK 11107767A HK 1153648 A1 HK1153648 A1 HK 1153648A1
Authority
HK
Hong Kong
Prior art keywords
sclerostin
cells
sost
seq
expression
Prior art date
Application number
HK11107767.3A
Other languages
English (en)
French (fr)
Chinese (zh)
Other versions
HK1153648B (en
Inventor
May S. Kung Sutherland
James C. Geoghegan
Changpu Yu
John Latham
Original Assignee
Ucb Manufacturing, Inc.
May S. Kung Sutherland
James C. Geoghegan
Changpu Yu
John Latham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Manufacturing, Inc., May S. Kung Sutherland, James C. Geoghegan, Changpu Yu, John Latham filed Critical Ucb Manufacturing, Inc.
Publication of HK1153648A1 publication Critical patent/HK1153648A1/en
Publication of HK1153648B publication Critical patent/HK1153648B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)

Claims (7)

  1. Verfahren zum Identifizieren eines Faktors, der SOST-Expression verringert, umfassend:
    (a) Zusetzen von Osteoblasten-induzierenden Medien oder knochenmorphogenetischem Protein zu einer Mesenchymzelle;
    (b) Inkontaktbringen der Zelle mit einem Testagens und
    (c) Detektieren, ob endogene SOST-Expression abnimmt.
  2. Verfahren gemäß Anspruch 1, wobei die Zelle eine Nukleinsäure umfasst, die ein Protein codiert, das SEQ ID NO:3 oder SEQ ID NO:6 oder SEQ ID NO:8 umfasst.
  3. Verfahren gemäß Anspruch 1, wobei die Nukleinsäure SEQ ID NO:1 oder SEQ ID NO:2 oder SEQ ID NO:5 oder SEQ ID NO:7 umfasst.
  4. Verfahren gemäß Anspruch 1, wobei die Zelle eine humane Mesenchymzelle ist.
  5. Verfahren zum Identifizieren eines Antagonisten für Sclerostin, umfassend:
    (a) Inkontaktbringen einer Zelle mit Sclerostin und einem Testagens und
    (b) Detektieren, ob das Testagens eine Apoptose der Zelle verhindert.
  6. Verfahren gemäß Anspruch 5, wobei die Zelle eine Mesenchymzelle ist.
  7. Verfahren gemäß Anspruch 6, wobei die Zelle eine humane Mesenchymzelle ist.
HK11107767.3A 2002-03-01 2011-07-26 Methods for increasing or decreasing bone density and identifying molecules HK1153648B (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US36125802P 2002-03-01 2002-03-01
US361258P 2002-03-01
US40617102P 2002-08-27 2002-08-27
US406171P 2002-08-27
US44739303P 2003-02-13 2003-02-13
US447393P 2003-02-13

Publications (2)

Publication Number Publication Date
HK1153648A1 true HK1153648A1 (en) 2012-04-05
HK1153648B HK1153648B (en) 2013-04-12

Family

ID=

Also Published As

Publication number Publication date
EP2277522A2 (de) 2011-01-26
EP1575481A2 (de) 2005-09-21
US7655420B2 (en) 2010-02-02
AU2003223214A1 (en) 2003-09-16
WO2003073991A3 (en) 2007-02-22
CA2476410A1 (en) 2003-09-12
US7332276B2 (en) 2008-02-19
JP2010213708A (ja) 2010-09-30
US20080227138A1 (en) 2008-09-18
US20030229041A1 (en) 2003-12-11
US8227441B2 (en) 2012-07-24
EP2277522B1 (de) 2012-11-21
CA2476410C (en) 2013-09-24
US20110009467A1 (en) 2011-01-13
EP1575481A4 (de) 2010-01-06
JP2005532998A (ja) 2005-11-04
JP4662714B2 (ja) 2011-03-30
WO2003073991A2 (en) 2003-09-12
EP2277522A3 (de) 2011-04-20
AU2003223214B2 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
EP2277522B1 (de) Verfahren zur Erhöhung oder Verminderung der Knochendichte und zur Identifizierung von Molekulen
Han et al. T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1β in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy
Monkawa et al. Identification of 25-hydroxyvitamin D3 1α-hydroxylase gene expression in macrophages
Gurates et al. WT1 and DAX-1 inhibit aromatase P450 expression in human endometrial and endometriotic stromal cells
Tsourdi et al. Hyperthyroidism and hypothyroidism in male mice and their effects on bone mass, bone turnover, and the Wnt inhibitors sclerostin and dickkopf-1
Ferron et al. Inositol polyphosphate 4-phosphatase B as a regulator of bone mass in mice and humans
Scheiber et al. Endoplasmic reticulum stress is induced in growth plate hypertrophic chondrocytes in G610C mouse model of osteogenesis imperfecta
Horsch et al. Mitogen-activated protein kinase phosphatase 1/dual specificity phosphatase 1 mediates glucocorticoid inhibition of osteoblast proliferation
Nathwani et al. Regulation of gonadotropin-releasing hormone and its receptor gene expression by 17β-estradiol in cultured human granulosa-luteal cells
Liu et al. Impaired osteogenic differentiation associated with connexin43/microRNA-206 in steroid-induced avascular necrosis of the femoral head
Avnet et al. Osteoblasts from a mandibuloacral dysplasia patient induce human blood precursors to differentiate into active osteoclasts
Seok et al. Dexras1 plays a pivotal role in maintaining the equilibrium between adipogenesis and osteogenesis
Kanda et al. Prostaglandin E2 suppresses CCL27 production through EP2 and EP3 receptors in human keratinocytes
Huang et al. miR-122–5p targets GREM2 to protect against glucocorticoid-induced endothelial damage through the BMP signaling pathway
Xiong et al. ATP6AP2, a regulator of LRP6/β-catenin protein trafficking, promotes Wnt/β-catenin signaling and bone formation in a cell type dependent manner
WO2000046348A1 (fr) Procede permettant d'induire une differenciation dans les adipocytes, compose regulant cette differenciation et procede de criblage correspondant
van Zeijl et al. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients
JP2008521446A (ja) グルコース輸送関連遺伝子、ポリペプチド、およびその使用方法
Yuan et al. Reduced APPL1 impairs osteogenic differentiation of mesenchymal stem cells by facilitating MGP expression to disrupt the BMP2 pathway in osteoporosis
HK1153648B (en) Methods for increasing or decreasing bone density and identifying molecules
Fairfield et al. Targeting bone cells during sexual maturation reveals sexually dimorphic regulation of endochondral ossification
WO1999061044A9 (en) Noggin and antagonists of bone morphogenetic proteins to suppress pathologic bone resorption
Qiu et al. Impairment of primary cilia contributes to visceral adiposity of high fat diet‐fed mice
Hashimoto et al. Effects of mifepristone on adipocyte differentiation in mouse 3T3-L1 cells
Kemmotsu et al. Antenatal administration of betamethasone contributes to intimal thickening of the rat ductus arteriosus

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200225